Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28806298 | 0.89 | DRD2 (0.46) | OPRD1OPRK1TACR1TSHRALOX15 | |
| SCHEMBL4407822 | 0.85 | OPRD1 (0.47) | OPRD1OPRK1TACR1TSHRALOX15 | |
| SCHEMBL521464 | 0.85 | NR1H2 (0.48) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL6160544 | 0.85 | CNR1 (0.47) | OPRD1OPRK1TACR1TSHRALOX15 | |
| SCHEMBL7831565 | 0.84 | GPR119 (0.54) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL4293214 | 0.83 | OPRM1 (0.49) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL29892887 | 0.83 | STS (0.50) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL3028439 | 0.83 | STS (0.50) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL19690249 | 0.83 | TSHR (0.46) | OPRD1OPRK1TACR1ALDH1A1TSHR | |
| SCHEMBL2582728 | 0.82 | TACR1 (0.51) | OPRD1OPRK1TACR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1740169-B | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC | 2010-04-21 | — | — | CN | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-1740169-A | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| CN-1230431-C | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2005-12-07 | — | — | CN | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| CN-1439003-A | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | OPRD1 1304/4885OPRK1 490/4885TACR1 289/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | OPRD1 1304/4885OPRK1 490/4885TACR1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.